NCT01468350

Safety and Tolerability of Dalfampridine in Subjects With Cerebral Palsy

A Double-Blind, Placebo-Controlled, Crossover Study in Subjects With Cerebral Palsy to Evaluate the Safety and Tolerability and the Effect on Sensorimotor Function of Dalfampridine-ER

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 35 (actual)
• Sponsor: Acorda Therapeutics · Industry
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

A double-blind, placebo-controlled, crossover study in subjects with cerebral palsy (CP) to evaluate the safety and tolerability and the effect of dalfampridine extended release (ER) tablets on sensorimotor function

Conditions

• Cerebral Palsy (CP)

Interventions

Type	Name	Description
DRUG	dalfampridine-ER 10mg
OTHER	Placebo

Timeline

• Start date: 2011-12-01
• Primary completion: 2013-01-01
• Completion: 2013-03-01
• First posted: 2011-11-09
• Last updated: 2014-06-24
• Results posted: 2014-06-24

Locations

11 sites across 1 country: United States